Premium
Identification of Serum Protein Markers for Breast Cancer Relapse With SELDI‐TOF MS
Author(s) -
Lei Lei,
Wang XiaoJia,
Zheng ZhiGuo,
Huang Jian,
Cao WenMing,
Chen ZhanHong,
Shao XiYing,
Cai JuFen,
Ye WeiWu,
Lu HongYang
Publication year - 2011
Publication title -
the anatomical record: advances in integrative anatomy and evolutionary biology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.678
H-Index - 62
eISSN - 1932-8494
pISSN - 1932-8486
DOI - 10.1002/ar.21399
Subject(s) - breast cancer , medicine , biomarker , oncology , cancer , biology , biochemistry
Surface‐enhanced laser desorption/ionization time‐of‐flight mass spectrometry (SELDI‐TOF MS) was used to screen serum samples to identify protein markers for early breast cancer relapse. We collected 67 serum samples from patients with breast cancer (24 preoperative; 23 postoperative without breast cancer relapse; 20 postoperative with breast cancer relapse). Eight protein peaks varied between the presurgical group and the postsurgical group without breast cancer relapse; 4 protein peaks were differentially expressed between the postsurgical patients without relapse and patients with relapse. The peak at 3964 m/z dropped after surgery and rebounded after relapse ( P < 0.01). These results indicate that there are differences in serum protein expression among the three different groups of patients. SELDI‐TOF MS could be used to screen blood samples for the early detection of relapse in primary breast cancer patients. Specifically, protein peak at 3964 m/z is a potential biomarker for the detection of early breast cancer relapse. Anat Rec, 2011. © 2011 Wiley‐Liss, Inc.